PPT-A Randomized Trial Comparing a Polymer-Free Coronary Drug-Eluting Stent With an Ultra-Thin

Bioresorbable PolymerBased DrugEluting Stent in an AllComers Patient Population Lisette Okkels Jensen Michael Maeng Bent Raungaard Johnny Kahlert Julia Ellert Lars Jakobsen . Dalby. , Munich, ESC2008. Update about the OCT data of the . Translumina. DES and competitors. A . Randomised. . optical. . coherence. . tomography. . study. . to. . determine. 90 . day. . stent. January 15. th. , 2016. 10h30. What is/are the best antithrombotic treatment(s) in case of stent thrombosis?. A. ). . 75mg . of . clopidogrel. B). 150mg . of . clopidogrel. C). 90mg x 2 . of . ticagrelor. , MD . PhD. Thoraxcentrum Twente, MST, Enschede, the . Netherlands. on. . behalf. of the BIO-RESORT . Investigators. BIO-RESORT . (TWENTE III):. A prospective, randomized, . three-arm . trial comparing two different biodegradable polymer-based drug-eluting stents and a durable polymer-based drug-eluting stent in . Randomised multicenter trial comparing. . . Optimax. . titanium-nitride-oxide coated stent . versus. . . Promus-Element. . stent. Tuomas Kiviniemi, MD, PhD. Turku University Hospital. Finland. Potential conflicts of interest. Second Generation Drug-eluting Stents Using. Either Biodegradable Polymer or Durable Polymer. The NOBORI . Biolimus. -Eluting versus . XIENCE/PROMUS . Everolimus. -eluting Stent Trial (NEXT). Masahiro . Comparing Second Generation Drug-eluting Stents Using. Either Biodegradable Polymer or Durable Polymer. The NOBORI . Biolimus. -Eluting versus XIENCE/PROMUS . Everolimus. -eluting Stent Trial (NEXT). b. A. lloon. for in-stent . Re. stenosis). José PS Henriques, MD. Jan Baan, MD. Academic Medical Center . Amsterdam, The Netherlands. A randomized comparison of paclitaxel-eluting balloon* versus . Fig. 1.Initial, postprocedural and followup angiograms of case 1. A instent restenosis of the bare metal stent in the proximal left anterior descen - ding artery. B postprocedural angiogram after perf fact, the first BP stentwas made of polyesters. Poly(orthoesters), polyanhydrides, and polyphosphazenes are alsobeing actively investigated.DEGRADATION OF POLYMERSDegradation of polymers generally ref randomized. trial in all-. comer. patients . treated. . with. . contemporary. DES. Marlies M. Kok, MD. Thoraxcentrum. Twente, MST, Enschede, the . Netherlands. On . behalf. of the BIO-RESORT . Zach Eddy, Category Advisor. 2. What are drug-eluting coronary stents?. Design. Expandable wire mesh tube. Coated with an antiproliferative drug. Pre-mounted on a balloon catheter delivery system. Function. : The. . HOST. -Reduce-. Polytech. -. ACS. . trial. Hyo-Soo Kim, MD/PhD. Cardiovascular Center,. Seoul National University Hospital, Korea. Session of Late Breaking Trial Session IV. Co-sponsored by European Heart Journal. Present and Future. Taehoon. . Ahn. , MD, PhD, FSCAI, FACC. Gachon. University Gil Medical Center . Incheon, South Korea. JCR2016. Conflict of interest: Nothing to report. Disclosure. Current situation of Korea made drug-eluting stents in Korea . Polymer-Based DES Compared with an Ultra-Thin Strut Bioresorbable . Polymer-Based DES in an All-Comers Patient Population. Clemens von Birgelen, MD PhD FESC. Thoraxcentrum. . Twente. , MST, . Enschede.